The analysis of VH and VL sequences of the identified, highly diverse sets of target-specific hits provides excellent evidence for the power of the MAB Discovery workflow. Furthermore, it provides the basis to identify potential CMC liability hotspots, to introduce modifications and to select the right set of antibodies for recombinant production. Remarkably, there is a significant contribution to diversity by the CDRs 1 and 2 in addition to CDR3 in both heavy and light chain sequences. This cannot be seen in transgenic animals or by employing alternative technologies.

< back